BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23031619)

  • 1. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
    Saadatmand S; Rutgers EJ; Tollenaar RA; Zonderland HM; Ausems MG; Keymeulen KB; Schlooz-Vries MS; Koppert LB; Heijnsdijk EA; Seynaeve C; Verhoef C; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MM
    BMC Cancer; 2012 Oct; 12():440. PubMed ID: 23031619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
    Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
    FH01 collaborative teams
    Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tailored Breast Screening Trial (TBST)].
    Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
    Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Choices for women at risk of hereditary breast cancer].
    Saadatmand S; Obdeijn IM; Koppert LB; Tilanus-Linthorst M
    Ned Tijdschr Geneeskd; 2013; 157(43):A6625. PubMed ID: 24152366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
    Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
    Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
    Geuzinge HA; Heijnsdijk EAM; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
    Breast; 2021 Apr; 56():1-6. PubMed ID: 33515770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.
    Lord SJ; Lei W; Craft P; Cawson JN; Morris I; Walleser S; Griffiths A; Parker S; Houssami N
    Eur J Cancer; 2007 Sep; 43(13):1905-17. PubMed ID: 17681781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier detection of breast cancer by surveillance of women at familial risk.
    Tilanus-Linthorst MM; Bartels CC; Obdeijn AI; Oudkerk M
    Eur J Cancer; 2000 Mar; 36(4):514-9. PubMed ID: 10717529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
    Kuhl C; Weigel S; Schrading S; Arand B; Bieling H; König R; Tombach B; Leutner C; Rieber-Brambs A; Nordhoff D; Heindel W; Reiser M; Schild HH
    J Clin Oncol; 2010 Mar; 28(9):1450-7. PubMed ID: 20177029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
    Kriege M; Brekelmans CT; Obdeijn IM; Boetes C; Zonderland HM; Muller SH; Kok T; Manoliu RA; Besnard AP; Tilanus-Linthorst MM; Seynaeve C; Bartels CC; Kaas R; Meijer S; Oosterwijk JC; Hoogerbrugge N; Tollenaar RA; Rutgers EJ; de Koning HJ; Klijn JG
    Breast Cancer Res Treat; 2006 Nov; 100(1):109-19. PubMed ID: 16791481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.